Bioatla Inc (BCAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.89M
Last updated: Nov 16, 2026 at 4:00 PM ET
Bioatla Inc (BCAB) Statistics
Bioatla (BCAB) has a market cap of $2.89M and an enterprise value of $2.31M. It kept -269.41% of revenue as net income over the last 12 months. Its share count is up 41.81% from a year earlier.
Total Valuation
Enterprise value is 19.93% below the market cap, as cash exceeds debt.
| Market Cap | $2.89M |
|---|---|
| Enterprise Value | $2.31M |
| Close (Nov 16, 2026) | $1.99 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 6, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 93.97% over 52 weeks and trades 22.09% above its 50-day average.
| Beta (1Y) | 0.26 |
|---|---|
| 52-Week Change | -93.97% |
| 1-Month Change | +46.32% |
| 3-Month Change | -37.42% |
| 6-Month Change | -49.23% |
| 5-Year Change | -99.86% |
| Total Return (1Y) | -93.97% |
| Total Return (3Y CAGR) | -71.01% |
| Total Return (5Y CAGR) | -72.98% |
| Return vs SPY (1Y) | -108.30% |
| Max Drawdown (1Y) | -98.23% |
| Max Drawdown (3Y) | -99.45% |
| Sharpe Ratio (1Y) | -2.12 |
| Correlation with SPY (1Y) | 0.02 |
| 50-Day Average | $1.63 |
| 200-Day Average | $4.30 |
| 52-Week Range | $1.07 to $71.50 |
| RSI (14 Days) | 55.5 |
| Average Volume (20 Days) | 6.73K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.05x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.05x |
|---|---|
| Quick Ratio | 0.05x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | -2125.61% |
|---|---|
| ROIC (5Y Average) | 131.96% |
| Asset Turnover | 1.03x |
| Receivables Turnover | 8.75x |
Scores
BCAB has an Altman Z-Score of -790.13, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -790.13 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $8.75M over the last 12 months.
| Revenue | $8.75M |
|---|---|
| Gross Profit | $8.75M |
| Operating Income | -$26.69M |
| Pretax Income | -$23.54M |
| Net Income | -$23.57M |
| Reported EPS (TTM) | -$17.89 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $576.00K |
|---|---|
| Total Debt | $0 |
| Net Cash | $576.00K |
| Net Cash Per Share | $0.35 |
| Working Capital | -$19.75M |
| Shareholder Equity | -$43.60M |
| Total Assets | $1.11M |
| Total Liabilities | $44.70M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$14.57M |
|---|---|
| FCF Per Share | -$8.74 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -305.04%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -305.04% |
| Pretax Margin | -269.02% |
| Net Margin | -269.41% |
Dividends and Yields
BCAB does not pay a dividend.
| Buyback Yield | -14.14% |
|---|---|
| Shareholder Yield | -14.14% |
Stock Splits
The last split was a 1-for-50 reverse split on Apr 6, 2026.
| Last Split Date | Apr 6, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:50 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BCAB
What is BCAB's market cap?
Bioatla has a market cap of $2.89M. Its enterprise value, which adds debt and subtracts cash, is $2.31M.
How many shares of BCAB are outstanding?
Bioatla has 1.67M shares outstanding. The count is up 41.81% from a year earlier.
Does BCAB pay a dividend?
No. Bioatla does not pay a dividend.
How much debt does BCAB have?
Bioatla has $0 of total debt and $576.00K of cash and equivalents, a net cash position of $576.00K.
BCAB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors